Bryn Mawr Trust CO Incyte Corp Transaction History

Bryn Mawr Trust CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Oct 28, 2025	BUY	$67.27 - $86.96 $134 - $173	2 Added 1.38%	147 $12,000
Q2 2025 Jul 28, 2025	SELL	$55.17 - $71.22 $55 - $71	-1 Reduced 0.68%	145 $9,000
Q3 2024 Nov 25, 2024	SELL	$57.33 - $68.61 $710,089 - $849,803	-12,386 Reduced 98.83%	146 $9,000
Q4 2021 Feb 10, 2022	SELL	$63.34 - $74.11 $31,670 - $37,055	-500 Reduced 3.84%	12,532 $920,000
Q1 2021 Apr 23, 2021	BUY	$76.02 - $100.5 $38,010 - $50,250	500 Added 3.99%	13,032 $1.06 Million

Q1 2020 May 08, 2020	BUY	$63.18 - $85.97 $791,771 - $1.08 Million	12,532 New	12,532 $918,000

800

205M

638K

635K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $23.2B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Bryn Mawr Trust CO, based on Form 13F filings with the SEC.

Stay updated on Bryn Mawr Trust CO with notifications on news.